Skip to Main content Skip to Navigation
Journal articles

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay 1 Jacques Cadranel 2, 3, 4 Amélie Lusque 5 Nicolas Meyer 6 Valérie Gounaut 7 Denis Moro-Sibilot 8 Jean-Marie Michot 9, 10 Judith Raimbourg 11, 12 Nicolas Girard 13 Florian Guisier 14, 15 David Planchard Anne-Cécile Metivier 16 Pascale Tomasini 17 Eric Dansin 18 Maurice Pérol 19 Marion Campana 20 Oliver Gautschi 21 Martin Früh 22 Jean-David Fumet 23 Clarisse Audigier-Valette 24 Sébastien Couraud 25, 26 Stéphane Dalle 27, 28 Marie-Thérèse Leccia 29 Marion Jaffro 30 Samia Collot 30 Gregoire Prevot 1 Julie Milia 1 Julien Mazières 1, *
* Corresponding author
12 CRCNA / Equipe 9 - Apoptose et Progression tumorale
INSERM - Institut National de la Santé et de la Recherche Médicale : U892, IRS-UN - Institut de Recherche en Santé de l'Université de Nantes
Abstract : Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event.Between December 2015 and April 2016, we conducted a retrospective study in centres experienced in ICI use. We report the main features of ICI-ILD with a focus on clinical presentation, radiological patterns and therapeutic strategies.We identified 64 (3.5%) out of 1826 cancer patients with ICI-ILD. Patients mainly received programmed cell death-1 inhibitors. ILD usually occurred in males, and former or current smokers, with a median age of 59 years. We observed 65.6% grade 2/3 severity, 9.4% grade 4 severity and 9.4% fatal ILD. The median (range) time from initiation of immunotherapy to ILD was 2.3 (0.2-27.4) months. Onset tended to occur earlier in lung cancer versus melanoma: median 2.1 and 5.2 months, respectively (p=0.02). Ground-glass opacities (81.3%) were the predominant lesions, followed by consolidations (53.1%). Organising pneumonia (23.4%) and hypersensitivity pneumonitis (15.6%) were the most common patterns. Overall survival at 6 months was 58.1% (95% CI 37.7-73.8%).ICI-ILD often occurs early and displays suggestive radiological features. As there is no clearly identified risk factor, oncologists need to diagnose and adequately treat this adverse event.
Complete list of metadatas

Cited literature [41 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01819272
Contributor : Elizabeth Bernardo <>
Submitted on : Wednesday, June 20, 2018 - 11:09:54 AM
Last modification on : Wednesday, April 1, 2020 - 12:04:04 PM
Document(s) archivé(s) le : Monday, September 24, 2018 - 2:52:31 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Citation

Myriam Delaunay, Jacques Cadranel, Amélie Lusque, Nicolas Meyer, Valérie Gounaut, et al.. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European Respiratory Journal, European Respiratory Society, 2017, 50 (5), ⟨10.1183/13993003.00050-2017⟩. ⟨inserm-01819272⟩

Share

Metrics

Record views

366